Eli Lilly in United States — Metabolic: the full competitive set, and the 3 AXLRx reports covering them with market-access, payer and competitive detail, every figure verified to a live source.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage.